STUDY OF THE INFLUENCE OF EXCIPIENTS ON THE QUALITY INDICATORS OF ANTI-DIABETIC DRUG IN THE FORM OF TABLETS
DOI:
https://doi.org/10.11603/2312-0967.2023.4.14393Keywords:
antidiabetic drug, core-tablets, excipients, pharmaco-technological indicators, quality indicators, mathematical modeling, dispersion analysis, desirability functionAbstract
The aim of the work is the selection of auxiliary substances, the study of their influence on the pharmaco-technological indicators of the tablet mass and tablets of the antidiabetic medicinal product.
Materials and Methods. Auxiliary substances from the groups of fillers, disintegrants and lubricants, as well as magnesium stearate as a lubricant, were used in the experiments. The research was carried out on modern equipment for determining: a tablet press (Korsh XL-100, Germany); the bulk density (ERWEKA SVM 202, Germany); the fluidity of powders (ERWEKA GT, Germany); resistance to crushing (ERWEKA TBH-525 WTO, Germany); abrasion resistance (ERWEKA TAR 200, Germany); decay (ERWEKA ZT 33, Germany). The active substance of the tablets of the antidiabetic drug is a pharmaceutically acceptable form based on the content of dapagliflozin 5 mg. The experimental data were subjected to statistical processing by the method of variance analysis. The desirability function is constructed.
Results and Discussion. According to the results of statistical processing of experimental data, the effect of excipients on the pharmaco-technological parameters of the tablet mass (bulk density, density after compaction, fluidity, slope angle), the tableting process and tablets (appearance, resistance to crushing, abrasion and disintegration) was investigated. Using the desirability function, the influence of the researched factors on the generalized quality indicators is shown.
Conclusions. The influence of excipients from the groups of fillers, disintegrants and glidants on the pharmaco-technological parameters of the tablet mass and tablets of the antidiabetic medicinal product with API – a pharmaceutically acceptable form of dapagliflozin – was studied. According to the results of dispersion analysis, ranked series of advantages were constructed. Using the desirability function, the conducted research allowed us to establish that the model compositions: a mixture of microcrystalline cellulose brand 102 with anhydrous lactose brand 22 AN in a ratio of 3:1, crospovidone XL-10 and silicon dioxide colloidal anhydrous (aerosil 200) and a mixture of microcrystalline cellulose brand 102 with anhydrous lactose brand 22 AN in a ratio of 3:1, sodium starch glycolate and PEG 8000 provide better indicators of fluidity, compressibility and quality of model tablet mass compositions and finished tablets.
References
World Health Organization. Fact Sheet Diabetes. 2022. URL: https://www.who.int/en/news-room/ fact-sheets/detail/diabetes.
PhRMA. Medicines in Development for Diabetes and Related Conditions. 2019. URL: https://www. phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/M-O/MID-Diabetes-Drug- List-2019.pdf.
Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales / A. D. Dahlen et al. Front. Pharmacology. 2021;12:1-16. DOI: https://doi.org/10.3389/fphar.2021.807548
Garcia-Ropero A, Badimon JJ. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opinion on Drug Metabolism and Toxicol. 2018;14(12):1287-302. DOI: https://doi.org/10.1080/17425255.2018.1551877
Singh M, Kumar A. Risks Associated with SGLT2 Inhibitors: An Overview. Current Drug Safety. 2018;13(2):2-3. DOI: https://doi.org/10.2174/1574886313666180226103408
Tiwari SS, Wadher SJ, Fartade SJ, Vikhar CN. Gliflozin a new class for type-II diabetes mellitus: an over¬view. Int J Pharm Sci & Res. 2019;10 (9):4070-7.
Dapagliflozin: MedlinePlus Drug Information. URL: https://medlineplus. gov/druginfo/meds/ a614015.html.
Macisaac RJ, Lee MH. Empagliflozin as adjunctive therapy for type 1 diabetes. Ann Transl Med. 2018;6(S-2):134. DOI: https://doi.org/10.21037/atm.2018.12.52
Hroshovyi TA. Mathematical planning of the experiment in conducting research in pharmacy. [Математичне планування експерименту при проведенні наукових досліджень у фармації] Ternopil: TSMU “Ukrmedkny¬ha”; 2008. Ukrainian.
State Pharmacopoeia of Ukraine: 3 Vol. Kharkiv: Ukrai¬nian Scientific Pharmacopoeia Center of Quality of Me¬dicinal Products. Ed.2. Vol.3. [Державна Фармакопея України: в 3 т./ Державне підприємство «Український науковий фармакопейний центр якості лікарських засобів». – 2-е вид., Т.3]: Kharkiv: Ukrainian Scientific Pharmacopoeia Center of Quality of Medicinal Prod¬ucts; 2014. Ukrainian.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pharmaceutical Review / Farmacevtičnij časopis

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
.
- Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).